Actively Recruiting
Phase 12 Study of AAVAnc80-antiVEGF Gene Therapy Delivered by Akouos Device for Adults With Unilateral Vestibular Schwannoma
Led by Akouos, Inc. · Updated on 2026-04-06
27
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF gene therapy in adults with unilateral vestibular schwannoma, a type of tumor affecting the ear. The trial also assesses the performance of the Akouos delivery device designed to safely deliver the gene therapy to the inner ear. This is a Phase 12 interventional trial sponsored by Akouos, Inc.
CONDITIONS
Brief Title
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Research Team
A
Akouos Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
